EMA bids to clarify API starting material info pharmas should provide

By Gareth Macdonald

- Last updated on GMT

iStock/Singkham
iStock/Singkham

Related tags European medicines agency Pharmaceutical drug Pharmacology

The EMA has revised its reflection paper on API starting materials to clarify what information drug firms should provide about their starting materials under ICH Q11.

The London-based European Medicines Agency (EMA) issued the document in July​, changing a section relating to starting materials in an explanatory note covering active pharmaceutical ingredient (API) manufacturing.

The revised reflection paper makes clear that if a chemical intermediate being used to make an API is an API the applicant can submit the certificate of suitability (CEP) – as well as details of manufacturers involved - instead of a detailed process description.

The new document also states that if the intermediate is already in an approved drug and documented in an ASMF, the applicant can reference the document.

Clarification

The original reflection paper, published in 2014​, defined “starting materials” as the first substance used in the production of an API and stressed that such compounds need to be produced in accordance with good manufacturing practice (GMP) standards.

However, while the terms were clear, the problem according to the European Medicines Agency (EMA) is that drug manufacturers and national regulators often disagree on what constitutes a starting material as a result of flexibility built into ICH Q11 guidelines.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars